Mxi-2 Dependent Regulation of p53 in Prostate Cancer

Background/Aim: Endothelin-1 (ET-1) is overexpressed in many types of cancer, inhibiting the release of the microRNA 15a (miR-15a) and inducing the production of Mxi-2. Our aim was to identify a molecular complex regulating p53 activity in prostate cancer (PCa). Materials and Methods: DU145 cells we...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2020-10, Vol.40 (10), p.5539-5544
Main Authors: KÖDITZ, BARBARA, FRIES, JOCHEN W.U., GÖBEL, HEIKE, PAFFENHOLZ, PIA, RICHTER, KONSTANTIN, HEIDENREICH, AXEL, VON BRANDENSTEIN, MELANIE
Format: Article
Language:English
Subjects:
Argonaute 2 protein
Endothelin 1
Endothelin ETA receptors
Endothelin ETB receptors
Enzyme-linked immunosorbent assay
Immunoprecipitation
Inhibitors
MAP kinase
MicroRNAs
miRNA
p53 Protein
Prostate cancer
Receptors
Ribonucleic acid
RNA
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Aim: Endothelin-1 (ET-1) is overexpressed in many types of cancer, inhibiting the release of the microRNA 15a (miR-15a) and inducing the production of Mxi-2. Our aim was to identify a molecular complex regulating p53 activity in prostate cancer (PCa). Materials and Methods: DU145 cells were treated with ET-1, MAPK p38 inhibitor, Endothelin A receptor inhibitor (ETAR inhibitor) and Endothelin B receptor inhibitor (ETBR inhibitor). Extracts were analysed using Western Blot, immunoprecipitation and qRT–PCR. Furthermore, prostate cancer patient samples were analysed using qRT–PCR and ELISA. Results: The hypothesised molecular complex was identified, with miR-15a, microRNA 1285 (miR-1285) and Mxi-2 levels up-regulated in patients in relation to increasing aggressiveness of PCa. Conclusion: A complex composed of Argonaut 2 (Ago2)/Mxi-2/miR-1285 is involved in PCa. The expression of Mxi-2 correlates with increasing PCa aggressiveness and might be used as a non-invasive marker for the diagnosis and progression of PCa.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.14566